@IsraelMFA You are disgusting and acting ILLEGALLY! STOP THIS GENOCIDE AND STARVATION OF INNOCENT CIVILIANS! The whole world can see what you are
Doing!!!!! Sickening! NO DIFFERENT TO HITLER
@m3658024941 @miabrenkill @IsraelMFA@Israel Are you deranged? Thousands of innocent civilians & children dead in Gaza you muppet. Starved, bombed, shot, denied medical aid. What the F is wrong with you. Its confirmed genocide and officially famine! Delivering aid to civilians who are starving is not terrorist supporting!
@j4ppleby@IsraelMFA Yeah all the Palestinian kids are Hamas you fool 🙄 IDF is starving innocent civilians and children and using HAMAS as an excuse! The whole world knows it! Bombing hospitals, safe zones, journalists, schools, destroying and killing everyone. The world will never forget this!
@v_freedman@afifahafra79@IsraelMFA Fkn rubbish! They are trying to help the INNOCENT CIVILIANS that the IDF are STARVING on purpose! Innocent civilians and children are NOT HAMAS!!!
@ReneNieuwenhuis@afifahafra79@IsraelMFA Israel are the ones blocking aid to Gaza and causing starvation! If they weren’t doing that, then there would be no need for Flotilla to deliver aid! It is a FAMINE in Gaza! Innocent children are being bombed and starved to death!
@MavenViews@IsraelMFA Rubbish! It has formally been declared in famine! IDF is BLOCKING aid distribution! Children are starving to death, but u are ok with that you monster! There was an official ceasefire back in January with confirmed release of hostages on both sides until IDF broke it by bombing!
Phase 1 trials: one in combination with PADCEV® (enfortumab vedotin-ejfv) in patients with urothelial cancer, and the other in combination with ENHERTU® (fam-trastuzumab deruxtecan-nxki) in patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.
#ICYMI: Bria-IMT™ + CPI produced cancer-fighting CD8+ T cells infiltration into metastatic tumors and lymphoid tissue, leading to cancer destruction - turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging. https://t.co/pifMBMjkJl $BCTX $BCTXW
#SABCS24
Bria-IMT™ combination regimen was associated with longer than expected PFS in a #clinicalstudy of 54 #MBC patients. If you or someone you know would like to participate in BCTX's pivotal Ph 3 study in #metastaticbreastcancer, please visit: https://t.co/MUhxzvXJe4 $BCTX $BCTXW
SCINTIX therapy is a new modality in radiotherapy. Following an injection with the radiotracer, fludeoxyglucose (FDG-18), tumors continuously generate signals detected by our X1 platform, to determine where radiation should be delivered. Learn more about this new option for patients at https://t.co/3ldpx5BXUM
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial out in @JCO_ASCO
The postMONARCH 🦋trial evaluated the efficacy of switching endocrine therapy (ET) with or without continued CDK4/6 inhibition using abemaciclib in patients with hormone receptor-positive (HR+), HER2-negative advanced #BreastCancer (ABC) who had progressed on prior CDK4/6 inhibitors. In this Phase III trial, 368 patients were randomized to receive either abemaciclib+fulvestrant or placebo+fulvestrant. The study found that abemaciclib+fulvestrant significantly improved progression-free survival (PFS) compared to placebo+fulvestrant, with a hazard ratio of 0.73 and a median PFS of 6.0 versus 5.3 months.
The treatment benefit was consistent across clinical and genomic subgroups, including patients with ESR1 or PIK3CA mutations. Additionally, the objective response rate (ORR) was higher with abemaciclib+fulvestrant (17% vs 7%), and no new safety concerns were observed, reinforcing abemaciclib's potential as an additional therapy option in this setting.
https://t.co/iSVGDhxWSH
@KalinskyKevin@BianchiniGP@ErikaHamilton9@DrSGraff@RMJesel@drumutdemirci@drsarahsam@MuozMateu@bastien_nguyen@smythlillian
Ping
#OncoAlertAF
@nataliagandur@acampsmalea @BiagioRicciutMD
@yekeduz_emre@HHorinouchi@FadiHaddad_MD@Dr_Ivanoncologo@Abdallah81MD@FernandoOnco@ElisaAgostinett@to_be_elizabeth@bavilima@realbowtiedoc@Erman_Akkus@Lucarecco
World First Study Published: Histotripsy for Canine Brain Tumors
Results have been published from the first clinical trial using histotripsy − a focused ultrasound technique − to treat brain tumors in dogs.
Highlights:
•Safety and feasibility of histotripsy for brain tumor ablation was established.
•Team included human and veterinary neurosurgeons and engineers at the @MedicalCollege, @NeuroBesta, @virginia_tech, and the @UMich.
•Study supports the development of transcranial histotripsy systems for both human and canine patients.
Read more about this innovative study which was co-funded by the Foundation: https://t.co/QU3gpgjuzp
treatment that uses sound waves to disintegrate tumors -
Histotripsy employs focused ultrasound to create microbubbles in tumors, generating forces that break apart the mass, eliminating tumor cells
Video has sound
HistoSonics, Inc. is excited to participate in #ASTRO2024 September 29th - October 1st in Washington, DC. with our now FDA cleared Edison Histotripsy System using non-invasive sonic beam therapy to destroy targeted tumors. "Meet Edison" at Booth #2709
⚠️ BREAKING:
U.S. 🇺🇸 Reports 5.236 million New COVID-19 Infections in One Week.
Currently, 1 in 64 Americans is Infected with COVID-19.
COVID-19 transmission is currently higher than it was during 73.3% of the pandemic.